临床儿科杂志 ›› 2020, Vol. 38 ›› Issue (10): 781-.doi: 10.3969/j.issn.1000-3606.2020.10.015

• 罕见病 疑难病 • 上一篇    下一篇

酪氨酸激酶抑制剂引起急性髓系白血病儿童身高增长障碍1例并文献复习

郑方圆,张乐萍   

  1. 北京大学人民医院儿科(北京 100044)
  • 出版日期:2020-10-15 发布日期:2020-10-10
  • 通讯作者: 张乐萍 电子信箱:zhangleping@pkuph.edu.cn

Height growth retardation in a child with acute myeloid leukemia caused by tyrosine kinase inhibitor: a case report and literature review

ZHENG Fangyuan, ZHANG Leping   

  1. Peking University People’s Hospital, Beijing 100044, China
  • Online:2020-10-15 Published:2020-10-10

摘要: 目的 探讨酪氨酸激酶抑制剂对急性髓系白血病儿童身高增长的影响。方法 回顾分析1例酪氨酸激酶抑 制剂引起急性髓系白血病身高增长障碍患儿的临床资料,并复习相关文献。结果 女性患儿,有一异卵双胎姐姐,姐妹出 生时体质量相近。患儿于19月龄时经临床、血常规、骨髓形态学、免疫学、分子及基因遗传学诊断为急性髓系白血病,基 因检测CBFβ-MYH11融合基因531.8%;c-kitD419-L421delins WN阳性,予以常规化疗。此时患儿与其同胞姐姐身高均处 于中国同年龄同性别儿童生长曲线P90。患儿诱导化疗结束后骨髓完全缓解,但CBFβ-MYH11基因未转阴,巩固化疗结束 后加用伊马替尼治疗后基因转阴,但患儿出现身高增长减慢(由P90下降至P75)。 患儿停用伊马替尼后身高增长速度有所 恢复。但因CBFβ-MYH11基因间断转阳,加用伊马替尼后,身高增长即减慢。以达沙替尼替代伊马替尼,身高增长仍减慢。 随访至9岁10个月时,患儿身高134 cm,位于P10~P25,而患儿同胞姐姐146 cm,仍处于P90。结论 酪氨酸激酶抑制剂可 引起急性髓系白血病儿童身高增长障碍。

关键词: 酪氨酸激酶抑制剂; 急性髓系白血病; 身高; 儿童

Abstract:  Objective To?explore?the?effect?of?tyrosine?kinase?inhibitor?on?height?growth?in?children?with?acute?myeloid? leukemia. Method? The?clinical?data?of?a?child?with?height?growth?retardation?caused?by?tyrosine?kinase?inhibitor?were? retrospectively?analyzed,?and?the?relevant?review?was?reviewed.?Results? The?female?child?had?a?fraternal?twin?sister?with?similar? body?weight?at?birth.?At?the?age?of?19?months,?the?child?was?diagnosed?of?acute?myeloid?leukemia?by?clinical,?blood?routine,?bone? marrow?morphology,?immunology,?molecular, ?and?genetic?genetics.?Genetic?detection?showed?CBFβ-MYH11?fusion?gene?(531.8%)? and?positive?c-kitD419-L42 1delins WN,?and?the?child?received?routine?chemotherapy.?At?that?time,?the?height?of?the?child?and?her? sibling?were?both?at?the?P90?of?the?growth?curve?of?the?same?age?and?sex?in?China.?The?child’s?bone?marrow?was?completely?relieved? after?induction?chemotherapy,?but?the?CBF -MyH11?gene?did?not?turn?negative.?After?the?consolidation?chemotherapy,?the?treatment? with?imatinib?was?added?and?the?gene?turned?negative,?but?the?child?showed?slower?growth?in?height?(from?P90 to P75).?After?the? cessation?of?imatinib,?the?growth?rate?of?height?recovered.?However,?due?to?intermittent?positive?of?CBFβ-MYH11?gene,?imatinib? was?added,?and?the?height?growth?was?reduced.?With?dasatinib?to?replace?imatinib,?the?increase?in?height?was?still?slowed?down.?At?9? years?and?10?months?of?the?follow-up,?the?height?of?the?child?was?134?cm?at?P10~P25,?while?her?sibling?sister?was?146?cm,?still?at?P90. Conclusion? Tyrosine?kinase?inhibitors?can?cause?height?growth?retardation?in?acute?myeloid?leukemia?child.

Key words:  tyrosine?kinase?inhibitor;? acute?myeloid?leukemia;? height;? child